



Contact	NMR spectrum (label and tolerance level of distances in Å)	Modelling (distances in Å)	
		MM2	AMBER*
4-18	M (2.3±0.5)	2.13	2.13
6-19s	V (3.5±1.5)	2.52	3.02
8-7s	S (2.5±1.0)	2.49	2.55
8-7r	S (2.5±1.0)	3.05	3.05
8-21	S (2.5±1.0)	2.15	2.12
10-11	V (3.5±1.5)	3.10	3.09
10-22	V (3.5±1.5)	5.98	2.27
11-10	V (3.5±1.5)	3.10	3.09
11-13	L (2.0±0.4)	3.39	2.38
11-21	V (3.5±1.5)	5.05	5.10
13-11	L (2.0±0.4)	3.39	2.38
14-16s	S (2.5±1.0)	3.01	3.84
14-22	M (2.3±0.5)	4.05	2.61
14-23r	V (3.5±1.5)	3.02	2.52
14-23s	L (2.0±0.4)	2.42	2.34
15-13	V (3.5±1.5)	2.95	3.77
15-17	V (3.5±1.5)	2.63	2.75
16s-17	S (2.5±1.0)	2.16	2.15
16s-14	S (2.5±1.0)	3.01	3.84
17-15	V (3.5±1.5)	2.63	2.75
19r-7s	S (2.5±1.0)	2.98	2.34
19s-7r	S (2.5±1.0)	4.35	3.12
21-7s	V (3.5±1.5)	2.55	2.54
21-7r	V (3.5±1.5)	2.68	2.86
4'-6'	M (2.3±0.5)	2.61	2.51
1''-6''	S (2.5±1.0)	4.40	4.43
4''-6''	M (2.3±0.5)	2.41	2.53
5''-4''	S (2.5±1.0)	3.06	2.51
6''-4''	M (2.3±0.5)	2.41	2.53
1'''-3'''	V (3.5±1.5)	3.89	2.45
2'''-1'''	M (2.3±0.5)	3.08	2.47
2'''OCH ₃ -1'''	S (2.5±1.0)	2.67	3.99
2'''OCH ₃ -3'''	S (2.5±1.0)	3.86	4.46
4'''-1'''	S (2.5±1.0)	2.49	3.93
6'''-1'''	S (2.5±1.0)	4.40	4.43
6'''-2'''	V (3.5±1.5)	2.22	4.07

Table S2: Distances obtained for tylosin A in chloroform using 2D ROESY NMR and molecular modelling; Symbols: L=Large, M=Medium, S=Small, V=Very small.

(a)



(b)



(c)




Figure S1: (a) Part of ^1H NMR spectrum of tylosin A in CDCl_3 from 0-2.3 ppm, (b) part of ^1H NMR spectrum of tylosin A in CDCl_3 from 2.3-5.3 ppm, (c) part of ^1H NMR spectrum of tylosin A in CDCl_3 from 5.6-9.8 ppm.





Figure S2: ^{13}C NMR spectrum of tylosin A in CDCl_3 .

(a)



(b)





Figure S3: (a) ¹³C DEPT 135 NMR spectrum of tylosin A in CDCl₃, (b) enlarged ¹³C DEPT 135 NMR spectrum of tylosin A in CDCl₃ from 55-90 ppm.






Figure S5: 2D HMBC NMR spectrum of tylosin A in CDCl_3 showing interactions belonging to tylosin A, but also the additional signals tentatively assigned to the degradant tylosin aldol. Circled peaks are not real HMBC cross peaks of tylosin A or do not belong to this compound.




Figure S6: 2D HMQC NMR of tylosin A in CDCl_3 showing interactions belonging to tylosin A, but also the additional signals tentatively assigned to the degradant tylosin aldol.




Figure S7: 2D ROESY NMR spectrum of tylosin A in CDCl_3 .




Figure S8: Interactions between (1) (pink) and the amino acids from chain B from *E. coli* ribosome.




Figure S9: Interactions between (2) (pink) and the amino acids from chain B from *E. coli* ribosome.




Figure S12: Interactions between (5) (pink) and the amino acids from chain B from *E. coli* ribosome




Figure S13: Interactions between (6) (pink) and the amino acids from chain B from *E. coli* ribosome.




Figure S14: Interactions between **(7)** (pink) and the amino acids from chain B from *E. coli* ribosome.




Figure S15: Interactions between **(8)** (pink) and the amino acids from chain B from *E. coli* ribosome.




Figure S16: Interactions between tildipirosin (pink) and the amino acids from chain B from *E. coli* ribosome.




Figure S17: Interactions between (**3**) (red) and the nucleotides from the binding site from *E. coli* ribosome.




Figure S18: Interactions between (5) (red) and the nucleotides from the binding site from *E. coli* ribosome.




Figure S19: Interactions between (6) (red) and the nucleotides from the binding site from *E. coli* ribosome.




Figure S20: Interactions between (2) (red) and the nucleotides from the binding site from *E. coli* ribosome.




Figure S21: Interactions between (4) (red) and the nucleotides from the binding site from *E. coli* ribosome.




Figure S22: Interactions between (1) (red) and the nucleotides from the binding site from *E. coli* ribosome.




Figure S23: Interactions between rosaramicin (red) and the nucleotides from the binding site from *E. coli* ribosome.




Figure S24: Interactions between **(8)** (red) and the nucleotides from the binding site from *E. coli* ribosome.




Figure S25: Interactions between **(7)** (red) and the nucleotides from the binding site from *E. coli* ribosome.




Figure S26: Interactions between erythromycin A (red) and the nucleotides from the binding site from *E. coli* ribosome.




Figure S27: Interactions between erythromycin B (red) and the nucleotides from the binding site from *E. coli* ribosome.




Figure S28: Interactions between erythromycin C (red) and the nucleotides from the binding site from *E. coli* ribosome.




Figure S29: Interactions between tylosin A (red) and the nucleotides from the binding site from *E. coli* ribosome.




Figure S30: Interactions between tylosin B (red) and the nucleotides from the binding site from *E. coli* ribosome.